northvalelabs.example

Prepared for Northvale Labs (sample client)

MARKETS ASSESSED	BUSINESS TYPE	REVIEW DATE	RULES VERSION
USA, UK, EU, Canada, Australia	Research peptides (RUO)	2 November 2026	2026.44



D

High risk

Overall compliance risk score, 19 findings

Score capped at 49 because at least one Critical finding is open.

2	8	6	3
CRITICAL	HIGH	MEDIUM	LOW

SCORES BY LAYER

Legal	15	Processor readiness	80
Privacy	76	Consumer protection	82
Best practice	92	Accessibility	98

TOP 3 ISSUES

ISSUE 1

CRITICAL

Pharma brand name on product

found on a product page

ISSUE 2

CRITICAL

Bacteriostatic multi-dose diluent listing

found on a product page and its label

ISSUE 3

HIGH

Trackers fire before cookie consent

found site-wide

16 further findings are in the Full Review

Exact locations, suggested replacement wording, legal references and a priority fix list are included in the Full Review.

Reply to this email to receive the Full Review. We will send an invoice and deliver the report the same day it is paid.

Rules version 2026.44, current as of 28 October 2026. This review is an automated and analyst-assisted assessment of risk indicators on the website at the date shown. It is not legal advice, does not certify compliance with any law, and does not guarantee approval by any payment processor or regulator. Rules change frequently; this review reflects rules version 2026.44 current as of 28 October 2026. Seek advice from a qualified lawyer in each market you sell into.